Shenogen Announces a New Member to Scientific Advisory Board: Dr. Michael Karin
April 2nd, 2014, Beijing, China
Shenogen Pharma Group announces the addition of Dr. Michael Karin to its Scientific Advisory Board (SAB). Dr. Michael Karin is a professor of Pharmacology and Pathology at the school of Medicine, University of California, San Diego.
“We are delighted to welcome Dr. Michael Karin to our SAB. He is a worldwide authority in signal transduction pathways involved in cellular stress, innate immunity, inflammation and cancer.” said Dr. Kun Meng, Chairman & CEO of Shenogen. “Dr. Karin has contributed a truly overwhelming wealth of discoveries and new insights relating to diverse biological processes. He’s currently working on understanding the link between inflammation, cancer and metabolic disease as well as the signaling mechanisms underlying. His work has revealed new targets for cancer prevention and therapy. That’s why we are certain that Dr. Karin’s join in will be quite beneficial to Shenogen R&D progress.”
“I’m very glad to join Shenogen. It is a promising company in China with innovative technology and cancer target. I’m looking forward to work with other talented scientists of Shenogen team, to make more contribution to anti-cancer drug R&D.” said Dr. Karin.
Dr. Karin was a cofounder of Signal Pharmaceutical (currently Celgene) and had served as a member of its Scientific Advisory Board. He also served as a member of the National Advisory Council for Environmental Health Sciences and has been an American Cancer Society Research Professor since 1999. Dr. Karin was elected as a member of the US National Academy of Sciences in 2005. Dr. Karin has published over 300 scientific articles and is an inventor on over 30 different patents or pending patent applications. He discovered and characterized key protein kinases, namely Jun kinase (JNK) that controls stress responses, and IκB kinase (IKK), a protein complex with a central role in the activation of the NF-κB pathway. In addition to numerous honors, Dr Karin was ranked first worldwide by the Institute of Scientific Information (ISI) in a listing of most-cited molecular biology and genetic research papers published in prestigious journals.
Dr. Karin joins Drs. Douglas Hanahan, V. Craig Jordan, Robert N. Eisenman and Changxiao Liu who are currently members of Shenogen’s Scientific Advisory Board.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.